LAS VEGAS — Intraosseous vancomycin infusion during total hip arthroplasty was feasible for timely delivery of periprosthetic infection prophylaxis, according to a presenter at the American Academy of ...

Despite IV Vancomycin’s Stronghold on the MRSA Antibiotic Hospital Market, Surveyed ID Specialists Report Shifting Away from IV Vancomycin to Branded Agents, Including Pfizer’s Zyvox and ...

Patients with Clostridium difficile infection warranting admission to the ICU may benefit from a treatment regimen of combined oral vancomycin and IV metronidazole, according to recent findings. In a ...

January 5, 2024 – Englewood, Colorado, Leiters Health is voluntarily recalling 33 lots of products listed below to the user level. The recalled batches of vancomycin IV bags, phenylephrine IV bags, ...

Treating hospitalized children with the widely used combination antibiotic therapy of intravenous vancomycin hydrochloride and piperacillin-tazobactam (TZP) significantly increases their risk for ...

February 13, 2012 (San Francisco, California) — Depositing vancomycin directly into deep spinal surgery wounds is associated with a low deep-infection rate, researchers reported here at the American ...

To date, the Company has not received any reports of adverse events related to this recall. Leiters Health is voluntarily recalling 33 lots of vancomycin intravenous (IV) bags, phenylephrine IV bags, ...

Credit: Shutterstock. Intravenous (IV) antibiotics such as CPT is indicated for ABSSSIs "but real world clinical comparative data is limited." This article is written live from ID Week 2017 Annual ...

New York, Dec. 15, 2004 – Surgical patients treated with Pfizer's novel antibiotic ZYVOX® (linezolid; injection, tablets, and for oral suspension) had a significantly higher rate of microbiologic ...

BOSTON, OCTOBER 1, 2004 – Treatment with ZYVOX® (linezolid injection, tablets and for oral suspension) for complicated skin and soft tissue infections (cSSTIs) caused by suspected or proven ...

PARSIPPANY, NJ--(Marketwire - Dec 20, 2012) - The Medicines Company (NASDAQ: MDCO) today announced results for its SOLO-1 Phase 3 clinical trial of oritavancin, which is under investigation for the ...